Trial reportParasites & vectors2018
Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome.
Trial report in Parasites & vectors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 4 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Diagnostic, prognostic, and therapeutic potentials of gut microbiome profiling in human schistosomiasis: A comprehensive systematic review.PLoS neglected tropical diseases · 2025Pooled it
- Schistosomiasis-Microbiota Interactions: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2024Pooled it
- Effects of Schistosoma haematobium infection and treatment on the systemic and mucosal immune phenotype, gene expression and microbiome: A systematic review.PLoS neglected tropical diseases · 2024Pooled it
- Pooled it
- Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases.Nature communications · 2022Trial
- Two key Actinomycetota taxa in the human gut microbiota are associated with Schistosoma mansoni infection burden.Parasitology research · 2026Article
- Article
- Article
- The dual role of intestinal parasites in shaping human gut microbiota: distinguishing helminthic and protozoan dynamics.Gut pathogens · 2026Review
- Profound taxonomic and functional gut microbiota alterations associated with trichuriasis: cross-country and country-specific patterns.NPJ biofilms and microbiomes · 2026Article
- Long Term Culture of Germ-Free Zebrafish Using Gamma-Irradiated Feeds.bioRxiv : the preprint server for biology · 2025Article
- High Schistosoma mansoni infection intensity is associated with distinct gut microbiota and low levels of systemic cytokines in children along the Albert-Nile, Northern Uganda.BMC microbiology · 2025Article
- Does schistosome infection affect behavior through the gut-brain axis?PLoS neglected tropical diseases · 2025Article
- Aligning antimicrobial resistance surveillance with schistosomiasis research: an interlinked One Health approach.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2024Review
- Gut microbiota and immune profiling of microbiota-humanised versus wildtype mouse models of hepatointestinal schistosomiasis.Animal microbiome · 2024Article
- Diversity and composition of gut protist in young rural Zimbabwean children.Frontiers in microbiomes · 2024Article
- Form and Function in the Digenea, with an Emphasis on Host-Parasite and Parasite-Bacteria Interactions.Advances in experimental medicine and biology · 2024Review
- A Scoping Review Evaluating the Current State of Gut Microbiota Research in Africa.Microorganisms · 2023Article
- Article
- The characteristics of intestinal microbiota in patients with chronic schistosomiasisFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundSchistosomiasis is a neglected tropical disease burdening millions of people. One drug, praziquantel, is currently used for treatment and control. Clinically relevant drug resistance has not yet been described, but there is considerable heterogeneity in treatment outcomes, ranging from cure to only moderate egg reduction rates. The objectives of this study are to investigate potential worm-induced dysbacteriosis of the gut microbiota and to assess whether a specific microbiome profile could influence praziquantel response.
methodsUsing V3 and V4 regions of 16S rRNA genes, we screened the gut microbiota of 34 Schistosoma mansoni infected and uninfected children from Côte d'Ivoire. From each infected child one pre-treatment, one 24-hour and one 21-day follow-up sample after administering 60 mg/kg praziquantel or placebo, were collected.
resultsOverall taxonomic profiling and diversity indicators were found to be close to a "healthy" gut structure in all children. Slight overall compositional changes were observed between S. mansoni-infected and non-infected children. Praziquantel treatment was not linked to a major shift in the gut taxonomic profiles, thus reinforcing the good safety profile of the drug by ruling out off-targets effects on the gut microbes.16S rRNA gene of the Fusobacteriales order was significantly more abundant in cured individuals, both at baseline and 24 hours post-treatment. A real-time qPCR confirmed the over-abundance of Fusobacterium spp. in cured children. Fusobacterium spp. abundance could also be correlated with treatment induced S. mansoni egg-reduction.
conclusionsOur study suggests that neither a S. mansoni infection nor praziquantel administration triggers a significant effect on the microbial composition and that a higher abundance of Fusobacterium spp., before treatment, is associated with higher efficacy of praziquantel in the treatment of S. mansoni infections.
trial registrationInternational Standard Randomised Controlled Trial, number ISRCTN15280205 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.